Biospective has a solid track-record of delivering top quality results in Phase Ib, Phase II, and Phase III studies across CNS therapeutic areas, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, ALS, neurodevelopmental disorders, and neuropsychiatric diseases. We are a full-service Core Imaging Lab and can provide expertise and services to support all of the demands of small to large-scale studies. Our advanced technologies (PIANO™ for fully-automated image processing, and GRETEL™ for web-based project and electronic data management, and high-throughput image QC review) set us apart from other CROs.
Consultation for Imaging Study Design
Imaging Site Management during Study
Statistical Image Analysis
Clinical Imaging Site Qualification
Rigorous Image Quality Control Review
Project and Data Management
Preparation of Image Acquisition Guidelines
Fully-automated, Multi-modality Image Processing
Biospective has substantial experience with a wide range of MRI (vMRI, fMRI, diffusion MRI/DTI, ASL MRI, SWI, neuromelanin), PET (amyloid, tau, FDG), and SPECT (DaTscan).
PIANO™ is our industry-leading, fully-automated image processing platform for clinical CNS studies. This 21 CFR Part 11 compliant, validated software includes core modules for all available MRI, PET, and SPECT neuroimaging techniques. The comprehensive, advanced, multi-modality capabilities of PIANO™ are unparalleled.
GRETEL™ is a cross-platform (computer, tablet, smartphone), modular, web-based application that provides full transparency into your clinical study. The power of the GRETEL™ Project and Electronic Data Management module stems from its ability to combine clinical, neuropsychiatric, imaging, and digital biomarker data from all subjects into a single, user-friendly system.